The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis

2021 ◽  
Vol 79 ◽  
pp. S1003
Author(s):  
M. Kardoust Parizi ◽  
V. Margulis ◽  
E.C. Compérat ◽  
S.F. Shariat
Keyword(s):  
Systematic Review ◽  
Cancer Treatment ◽  
Treatment Response ◽  
Bladder Carcinoma ◽  
Meta Analysis ◽  
Oncological Outcomes ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder

scholarly journals PD-1/PD-L1 Immune Checkpoint Inhibitors after Platinum-based Chemotherapy in Metastatic or Locally Advanced Urothelial Bladder Carcinoma: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Thara Tunthanathip ◽  
Tanan Bejrananda
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Cell Death ◽  
Bladder Carcinoma ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Second Line ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder ◽  
Line Chemotherapy

Objective: This study aimed to assess the effect of anti-programmed cell death-1/programmed cell death-ligand-1 (PD-1/PD-L1) agents compared with second-line therapy in patients with metastatic or locally advanced urothelial bladder carcinoma following previous platinum-containing chemotherapy.Material and Methods: We systematically searched three electronic databases. The protocol of the study was registered in Prospero (CRD42019142494). Using the Grading of Recommendations Assessment, Development, and Evaluation approach, the certainty of evidence (CoE) was estimated.Results: The search results initially found 8168 publications. For qualitative synthesis, two publications were included. Pooled results indicated that patients treated with anti-PD-1/PD-L1 agents had significantly prolonged overall survival (hazard ratio (HR) 0.80; 95% confidence interval (CI) 0.7-0.9; I2 21.0%; moderate CoE). According to positive PD-L1 expression, PD-1/PD-L1 inhibitors had significantly more survival than chemotherapy (HR 0.75; 95% CI 0.5-0.9, I2 57.0%, low CoE). Furthermore, there was no significant difference in adverse events (AE) between the anti-PD-1/PDL1 agents and second-line chemotherapy (risk ratio 0.68; 95% CI 0.3-1.4; I2 97.0%, low CoE).Conclusion: The present meta-analysis and systematic review provide strong evidence that anti-PD-1/PD-L1 agents could improve overall survival and have similar results in AEs compared with second-line chemotherapy. Further studies will confirm the power of immunotherapy for the treatment of metastatic or locally advanced urothelial bladder carcinoma.

scholarly journals Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report

2018 ◽  
Author(s):  
Guido Giordano ◽  
Nunzio Olivieri ◽  
Mario D'Andrea ◽  
Tania Di Raimo ◽  
Erminia Manfrin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Case Report ◽  
Bladder Carcinoma ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder
Sign in / Sign up

Export Citation Format

Share Document